Your browser doesn't support javascript.
loading
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
Tada, Akio; Minami, Toshiyuki; Kitai, Hidemi; Higashiguchi, Yoko; Tokuda, Mayuko; Higashiyama, Tomoki; Negi, Yoshiki; Horio, Daisuke; Nakajima, Yasuhiro; Otsuki, Taiichiro; Mikami, Koji; Takahashi, Ryo; Nakamura, Akifumi; Kitajima, Kazuhiro; Ohmuraya, Masaki; Kuribayashi, Kozo; Kijima, Takashi.
Afiliación
  • Tada A; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Minami T; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan; Department of Thoracic Oncology, Hyogo Medical University, Nishinomiya, Hyogo, Japan. Electronic address: to-minami@hyo-med.ac.jp.
  • Kitai H; Department of Thoracic Oncology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Higashiguchi Y; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Tokuda M; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Higashiyama T; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Negi Y; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan; Department of Thoracic Oncology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Horio D; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan; Department of Thoracic Oncology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Nakajima Y; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Otsuki T; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan; Department of Thoracic Oncology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Mikami K; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan; Department of Thoracic Oncology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Takahashi R; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan; Department of Thoracic Oncology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Nakamura A; Department of Thoracic Surgery, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Kitajima K; Department of Radiology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Ohmuraya M; Department of Genetics, Hyogo Medical University, Nishinomiya, Japan.
  • Kuribayashi K; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan; Department of Thoracic Oncology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Kijima T; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan; Department of Thoracic Oncology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
Lung Cancer ; 180: 107219, 2023 06.
Article en En | MEDLINE | ID: mdl-37146474
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de la Angiogénesis / Inhibidores de Proteínas Quinasas / Receptor de Muerte Celular Programada 1 / Mesotelioma Maligno / Indoles / Anticuerpos Monoclonales Límite: Animals / Female / Humans Idioma: En Revista: Lung Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de la Angiogénesis / Inhibidores de Proteínas Quinasas / Receptor de Muerte Celular Programada 1 / Mesotelioma Maligno / Indoles / Anticuerpos Monoclonales Límite: Animals / Female / Humans Idioma: En Revista: Lung Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Japón